Sapient

What is your tumor biology data not telling you? Join us for this live #webinar on July 23 to find out. Oncology programs often rely on DNA and RNA data to guide decisions – but genomics can only 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 target accessibility, pathway activity, and resistance. Protein-level measurements provide 𝐝𝐢𝐫𝐞𝐜𝐭 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 of this dynamic functional tumor biology. This webinar explores advancements that have made the functional tumor proteome accessible at scale in human tumors, across the dimensions that determine whether a drug will be effective in the patient tumor. See real-world examples of how these protein-level insights have revealed novel druggable targets, enabled deep characterization of immune and signaling activity, and uncovered resistance-associated biology that may be missed by sequencing alone. Register today: https://lnkd.in/gxDh6fEx

Introducing 𝐃𝐲𝐧𝐚𝐦𝐢𝐐™: your insights engine to accelerate drug development through rapid identification & validation of biomarkers and drug targets. Sapient's #multiomics database integrates a diverse breadth of dynamic molecular & clinical data collected in >62,000 serial samples to enable deep analysis of biomarker signatures, disease drivers & drug response. This deeply phenotyped database enables: ♾ 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐞𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭𝐬 using existing cohorts to find new biomarkers without the time & cost of collecting new samples. ♾ 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐫𝐢𝐬𝐨𝐧𝐬 within and across disease areas to identify shared or unique pathways to unlock 1) disease subtypes and 2) potential indication expansion. ♾ 𝐑𝐚𝐩𝐢𝐝 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 of targets & markers in independent cohorts to bridge the translational gap. Request a demo today! https://lnkd.in/gFAp6fSC

𝐍𝐞𝐰 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: With growing recognition that the heterogeneity in disease manifestation and complications of type 2 #diabetes (T2D) are not captured by conventional glycemic risk factors alone, this study sought to leverage discovery #metabolomics to identify novel etiologic #biomarkers of T2D. Published in 𝘋𝘪𝘢𝘣𝘦𝘵𝘦𝘴 𝘊𝘢𝘳𝘦, the findings show that diacylglycerols (DAGs) and phosphatidylcholines (PCs) are respectively associated with increased and decreased #T2D incidence, representing novel chemical classes of T2D risk predictors. https://lnkd.in/gzhmnnb6

📣 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐚𝐥𝐞𝐫𝐭: breakthrough rLC-MS metabolomics study in over 26,000 samples reveals metabolic aging clock and "metabotypes" of common diseases. This paper showcases the discovery power of Sapient's novel rLC-MS method by delivering 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐝𝐞𝐞𝐩, 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧-𝐬𝐜𝐚𝐥𝐞 𝐯𝐢𝐞𝐰 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐝𝐲𝐧𝐚𝐦𝐢𝐜 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐯𝐚𝐫𝐢𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧𝐬. In addition to identifying distinct metabolic phenotypes that strongly correlate with chronic diseases, the researchers used the large-scale dynamic metabolite & lipid measures to develop a machine learning–based metabolic aging clock that: 🕒 Accurately predicts accelerated biological aging in multiple chronic diseases 🕒 Shows reversal of metabolic age following treatments like organ transplantation This study and its findings exemplify the critical insights that can be extracted from large-scale metabolomics datasets. #metabolomics #populationstudies #rLC_MS #metabotypes #agingclock

You say you want a revolution? See how Sapient is leading the charge when it comes to #multiomics approaches that are transforming drug development. Singular omic approaches may miss critical interactions between genes, proteins, metabolites, and environmental factors, leading to incomplete understanding of disease mechanisms and drug response. In this feature article, we share how we're integrating diverse biological data to uncover deeper insights into health and disease – and importantly, applying those discoveries to help #pharma improve the success of therapeutic development. https://lnkd.in/gKQUeq4t #multiomicsleader #proteomics #metabolomics

Tumors aren't defined by a single biological dimension. Surface target accessibility, signaling pathway activation, immune function, and resistance mechanisms interact – continuously – to determine whether a therapy is effective. Reading any one of them in isolation is what produces the gap between "biologically rational" and "clinically successful." 𝐄𝐧𝐭𝐞𝐫 𝐒𝐚𝐩𝐢𝐞𝐧𝐭'𝐬 𝐓𝐮𝐦𝐨𝐫 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐌𝐚𝐩𝐩𝐢𝐧𝐠 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦: four mass-spectrometry-based proteomics workflows that measure these dimensions directly in human tumor tissue (fresh-frozen and FFPE): ✅ 𝐒𝐮𝐫𝐟𝐚𝐜𝐞𝐒𝐞𝐞𝐤™ – to identify druggable tumor cell surface proteins ✅ 𝐒𝐢𝐠𝐧𝐚𝐥𝐢𝐧𝐠𝐒𝐞𝐞𝐤™ – to measure phospho-driven pathway activation ✅ 𝐈𝐦𝐦𝐮𝐧𝐞𝐒𝐞𝐞𝐤™ – to quantify functional tumor immune biology ✅ 𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞𝐒𝐞𝐞𝐤™ – to map protein networks driving therapeutic resistance Whether used singularly or for integrated analyses, these workflow move oncology development beyond genomic inference to direct, multi-dimensional measurement of what's actually governing response. See how: https://lnkd.in/gZPNbCe7 #Oncology #Proteomics #TranslationalScience #DrugDevelopment